Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five years after paying $400 million for rights to the autoimmune disease drug candidate.

Getting back into running after a long break is a slog. Those first few workouts will make you wonder if you ever really enjoyed running in the first place. You can’t catch your breath. You’d swear ...

Runners often want to know how they compare to their peers when it comes to race times, workouts, and of course, mileage. That’s not to say you should try to match Fasty McFast who has been running ...